2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
复制标题
2021年美国风湿病学会类风湿关节炎治疗指南
DOI：
10.1002/acr.24596
复制
发表时间：
2021-07
影响因子：
4.7
通讯作者：
Akl, Elie A.
中科院分区：
文献类型：
--
作者：
Fraenkel, Liana;Bathon, Joan M.;England, Bryant R.;St Clair, E. William;Arayssi, Thurayya;Carandang, Kristine;Deane, Kevin D.;Genovese, Mark;Huston, Kent Kwas;Kerr, Gail;Kremer, Joel;Nakamura, Mary C.;Russell, Linda A.;Singh, Jasvinder A.;Smith, Benjamin J.;Sparks, Jeffrey A.;Venkatachalam, Shilpa;Weinblatt, Michael E.;Al-Gibbawi, Mounir;Baker, Joshua F.;Barbour, Kamil E.;Barton, Jennifer L.;Cappelli, Laura;Chamseddine, Fatimah;George, Michael;Johnson, Sindhu R.;Kahale, Lara;Karam, Basil S.;Khamis, Assem M.;Navarro-Millan, Iris;Mirza, Reza;Schwab, Pascale;Singh, Namrata;Turgunbaev, Marat;Turner, Amy S.;Yaacoub, Sally;Akl, Elie A.
美国风湿病学会（ACR）制定和/或认可的指南和建议旨在为常见的临床情况提供一般指导。这些建议并不指示对个别病人的护理。ACR认为遵守本指南中所述的建议是自愿的，其最终应用由临床医生根据每位患者的个人情况作出决定。指南和建议旨在促进有益或理想的结果，但不能保证任何具体的结果。根据医学知识、技术和实践的发展需要，由ACR制定和认可的指南和建议需要定期修订。ACR的建议并不打算决定支付或保险决策，或药物处方或其他第三方分析。引用ACR指南的第三方应声明，这些建议并非用于此目的。这些建议不能充分传达病人护理的所有不确定性和细微差别。美国风湿病学会是一个独立的、专业的医学和科学协会，不保证、保证或认可任何商业产品或服务。为类风湿关节炎的药理学治疗制定最新指南。我们提出了与临床相关的人群、干预、比较物和结果（PICO）问题。在进行了系统的文献综述后，采用分级建议评估、发展和评价（GRADE）方法对证据的确定性进行评级。由临床医生和患者组成的投票小组就建议的方向（支持或反对）和力度（强烈或有条件）达成共识。该指南涉及疾病改善抗风湿药物（DMARDs）的治疗，包括常规合成DMARDs、生物DMARDs和靶向合成DMARDs，糖皮质激素的使用，以及某些高危人群（即肝病、心力衰竭、淋巴增生性疾病、既往严重感染和非结核性支原性肺病患者）使用DMARDs。该指南包括44条建议（7条强烈建议，37条附带条件建议）。本临床实践指南旨在作为支持临床医生和患者决策的工具。建议不是规定性的，个体治疗决策应通过基于患者价值观、目标、偏好和合并症的共同决策过程做出。
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide general guidance for commonly encountered clinical scenarios. The recommendations do not dictate the care for an individual patient. The ACR considers adherence to the recommendations described in this guideline to be voluntary, with the ultimate determination regarding their application to be made by the clinicians in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions, or drug formularies or other third-party analyses. Third parties that cite ACR guidelines should state that these recommendations are not meant for this purpose. These recommendations cannot adequately convey all uncertainties and nuances of patient care. The American College of Rheumatology is an independent, professional, medical and scientific society that does not guarantee, warrant, or endorse any commercial product or service. To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. The guideline addresses treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional). This clinical practice guideline is intended to serve as a tool to support clinician and patient decision-making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision-making process based on patients’ values, goals, preferences, and comorbidities.
登录
查看更多内容
DOI：
10.1002/art.23716
发表时间：
2008-06-15
期刊：
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
影响因子：
--
作者：
Buchbinder, Rachelle;Barber, Melissa;Jolley, Damien
通讯作者：
Jolley, Damien
影响因子：
27.4
作者：
Emery, P.;Bingham, C. O., III;Weinblatt, M. E.
通讯作者：
Weinblatt, M. E.
影响因子：
3.9
作者：
Cantini, Fabrizio;Niccoli, Laura;Goletti, Delia
通讯作者：
Goletti, Delia
影响因子：
27.4
作者：
Burmester GR;Rigby WF;van Vollenhoven RF;Kay J;Rubbert-Roth A;Kelman A;Dimonaco S;Mitchell N
通讯作者：
Mitchell N
影响因子：
27.4
作者：
Detert, Jacqueline;Bastian, Hans;Burmester, Gerd-R
通讯作者：
Burmester, Gerd-R